Moberg Derma has announced the discontinuation of the development of Limtop, an actinic keratosis drug, as it failed to reach the predefined efficacy target in a completed phase II trial. Moberg Derma president and CEO Peter Wolpert said ...
Tags: drug, Moberg Derma, actinic keratosis drug